Driven by population increase, constant upscale and sophistication of Nigeria’s healthcare delivery, Fidson Healthcare plc is set to join the nation’s intravenous infusion market as it foresees N4 billion profit from its new product pipeline (intravenous (IV) infusion and injectables lines) by 2
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
BusinessDay
Nigeria's leading finance and market intelligence news report. Also home to expert opinion and commentary on politics, sports, lifestyle, and more
